Pruritus Therapeutics Market Report 2025 – Strategic Insights for Companies Seeking Expansion, Growth & Competitive Advantage

 Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

 
 What are the growth projections for the pruritus therapeutics market from 2024 to 2029?
 The pruritus therapeutics market size has grown strongly in recent years. It will grow from $11.89 billion in 2024 to $12.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to growth in the incidence of pruritus, diverse causes and conditions, rising aging population, and patient quality of life focus
 
 The pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $16.05 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expanding knowledge of pruritus pathophysiology, innovative drug formulations, and delivery, focus on personalized medicine, rise in dermatological research and development, increasing awareness and diagnosis rates, and growing interest in botanical and herbal remedies. Major trends in the forecast period include the development of itch-specific receptor agonists and antagonists, market emphasis on personalized therapeutic approaches, integration of technology in itch monitoring and management, and collaborations for cross-disciplinary research.
 
 Download Your Free Sample PDF:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp
 
 What strategic initiatives by market players are driving pruritus therapeutics industry growth?
 The rise in the incidence of dermatological disorders is expected to propel the growth of the pruritus therapeutics market going forward. Dermatological disorders refer to skin, hair, nail, and mucous membrane disorders ranging from acne and eczema to skin cancer and fungal infections. The underlying cause of itching often determines the use of pruritus treatments for dermatological illnesses. This condition uses topical treatments, emollients and moisturizers, immunosuppressant medications, and itching medications. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there will be 108,270 reported cases of skin cancer, reflecting a 3.2% increase from the 104,930 cases reported in 2023. Therefore, the rise in the incidence of dermatological disorders is driving the growth of the pruritus therapeutics market.
 
 What emerging segments are shaping the future landscape of the pruritus therapeutics industry?
 The pruritus therapeutics market covered in this report is segmented –
 
 1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
 2) By Route Of Administration: Oral, Parenteral, Topical
 3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
 4) By End-User: Hospitals, Clinics, Other End Users
 
 Subsegments:
 1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
 2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
 3) By Local Anesthetics: Topical Local Anesthetics
 4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
 5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants
 6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream
 7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies
 
 View The Full Market Report:
 https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report
 
 How are emerging trends transforming the pruritus therapeutics market dynamics?
 Major companies operating in the pruritus therapeutics market are focused on developing targeted treatments for rare diseases and specific patient populations. such as non-systemic ileal bile acid transport inhibitor to provide personalized medicine that addresses unmet medical needs. A non-systemic ileal bile acid transport inhibitor is a type of medication that targets bile acid absorption in the intestine without significantly affecting the systemic circulation, thereby minimizing potential side effects. For instance, in June 2023, Ipsen, a France-based pharma company, received the Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services, approval for Bylvay (odevixibat) for treating cholestatic pruritus in patients aged 12 months and older with Alagille syndrome (ALGS). Bylvay, a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), has minimal systemic exposure and is the first drug approved for cholestatic pruritus due to progressive familial intrahepatic cholestasis (PFIC) in the U.S. It was previously approved for PFIC treatment in Europe and is now available by prescription for eligible ALGS patients.
 
 How are key players in the pruritus therapeutics market strengthening their market position?
 Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.
 
 Which geographic areas are contributing significantly to the growth of the pruritus therapeutics sector?
 North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 How Can Companies Use The Pruritus Therapeutics Market Report to Drive Business Results?
 This report provides actionable insights tailored for business use — not academic analysis. Companies can leverage the data to:
 • Time market entry or expansion using growth forecasts and CAGR trends.
 • Develop competitive products by tracking key technology shifts and user preferences.
 • Tailor regional strategies with in-depth geographic data and local market dynamics.
 • Benchmark and plan partnerships using competitive landscape insights.
 
 Purchase The Report And Get A Swift Delivery:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11907
 
 Need Customized Data On Pruritus Therapeutics Market?
 For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
 
 Request Customized Data:
 https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
 
 Contact Us:
 
 The Business Research Company
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708
 
 Asia: +91 88972 63534
 
 Americas: +1 315 623 0293
 
 Email: info@tbrc.info
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company